106Ru/106Rh plaque radiotherapy for malignant melanomas of the choroid. With follow-up results more than 5 years.
Therapeutic results are presented with follow-up examinations of at least 5 years (min. 5 years, max. 22 years) after 106Ru/106Rh plaque radiotherapy of posterior uveal melanomas. Out of 227 patients 146 (= 64.3%) could be treated successfully, 37 (= 16.3%) had to be enucleated and are alive, 44 (= 19.4%) died from metastases and 40 (17.6%) from other causes. 75.0% of all small melanomas (T1a) showed an excellent regression pattern to flat scars. Five years after treatment the survival rate was 83.7% (deaths from any causes) respectively 88.2% (deaths from metastases only) and 64.8% (deaths from any causes) respectively 79.7% (deaths from metastases only) ten years after irradiation. 106Ru/106Rh plaque radiotherapy can be recommended for small (T1a, b) and medium sized (T2) choroidal melanomas.
Lommatzsch
P K
PK
Eye Hospital of the Karl-Marx-University Leipzig, GDR.
Kirsch
I H
IH
D001918:Brachytherapy / Q000009:adverse effects; D002830:Choroid Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D011832:Radiation Injuries; D011868:Radioisotopes / Q000627:therapeutic use; D012238:Rhodium / Q000627:therapeutic use; D012429:Ruthenium Radioisotopes / Q000627:therapeutic use; D013997:Time Factors; D014792:Visual Acuity
D011868:Radioisotopes; D012429:Ruthenium Radioisotopes; D012238:Rhodium